Imiquimod: An immune response modifier

Journal of the American Academy of Dermatology

Volumn 43, Issue 1 PART II, 2000, Pages

  Dahl, Mark V ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Box 98 FUMC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; COMPLEMENT; CYTOKINE; GAMMA INTERFERON; IMIQUIMOD; SYNTHETASE;

CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION; VIRUS REPLICATION;

AMINOQUINOLINES; BIOLOGICAL RESPONSE MODIFIERS; CONDYLOMATA ACUMINATA; HUMANS; IMMUNITY, CELLULAR; INTERFERON INDUCERS; VIRUS REPLICATION; WARTS;

EID: 0033923495     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.107809     Document Type: Article

References (14)

1. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
2. Mackenzie-Wood A, de Laudney J, Kossard S, Svans R, Fox T, Owens M. Safety and efficacy trial evaluating 5% imiquimod cream in the treatment of Bowen's disease with once daily application. Poster presented at the 56th Annual Meeting of the American Academy of Dermatology, Orlando, FL, Feb 27-May 4, 1998.
3. Vance JC, Bart BJ, Hansen RC, Reichman RC, McEwen C, Hatch KD, et al. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
4. Eron LJ, Judson F, Tucker S, Prawer S, Mills J, Murphy K, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-64.
5. Slade HB, Owens ML, Miller RL. Imiquimod 5% cream (Aldara). Exp Opin Invest Drugs 1998;7:437-49.
6. Beutner KR, Tyring SK, Trofatter KF Jr, Douglas JM Jr, Spruance S, Owens ML. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998;42:789-94.
7. Buckley R, Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol 1999;135:1167-9.
8. Imbertson LM, Beaurline JM, Couture AM, Gibson SJ, Smith RM, Miller RL, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9.
9. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998;178:551-5.
10. Burns RP Jr, Ferbel B, Tomai M, Miller R, Gaspari AA. The imidazoquinolines, imiquimod and R-848, induce functional but not phenotypic maturation of human epidermal Langerhans' cells. Clin Immunol 2000;94:13-23.
11. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25-30.
12. Happle R, Echternacht K. Induction of hair growth in alopecia areata with DNCB. Lancet 1977;2:1002-3.
13. Sidky YA, Bordon EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992;52:3528-33.
14. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg SE, et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993;53:5176-80.